Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition
0
Authors
Nathalie Jacque
Nathalie Jacque•Anne Ronchetti•Didier Bouscary
Published
July 18, 2015
Abstract
Key Points Genetic- or compound CB-839–induced GAC inhibition reduces OXPHOS and has antileukemic activity in AML. GAC inhibition synergizes with BCL-2 inhibition by compound ABT-199.
